{"ticker": {"uuid": "a411c6b6-f457-47e8-8454-8d835cc1fc3b", "symbol": "ALT", "name": "Altimmune Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?", "summary": "Despite Altimmune (ALT) stock experiencing a 45% drop over the last year, Wall Street analysts are projecting a significant upside, with an average 12-month price target of $18, suggesting a potential 495% increase from its current $3.02 trading price. Nine out of eleven analysts", "url": "https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK", "source_name": "Stocktwits", "published_at": "2026-07-16T18:41:22", "published_display": "16 Jul 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Altimmune gets analyst boost as MASH data grow", "summary": "Altimmune received an \"Outperform\" rating and a $10 price target from Leerink, a specialized healthcare investment bank, due to growing confidence in its drug pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). Clinical data from the IMPACT Phase 2b trial sho", "url": "https://longevity.technology/news/altimmune-gets-analyst-boost-as-mash-data-grow/", "source_name": "Longevity.Technology", "published_at": "2026-07-09T16:05:44", "published_display": "09 Jul 2026 16:05", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc. Actuals & Estimates (DUS:3G0)", "summary": "This article provides actual financial data and analyst estimates for Altimmune, Inc. (DUS:3G0), including income statements, balance sheets, and cash flow information. It details financial performance, future price forecasts from analysts, historical stock prices, and upcoming e", "url": "https://www.tradingview.com/symbols/DUS-3G0/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-07-09T04:39:58", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade (ALT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOUVc4OWdGMmZrVjh3dG9Kdlk4ejhsM1dMX3FQMHlCYng1cHBOVDdLV3BoMzk2ZnNMVllfZS1Eb25WTEtpbV8tYkppX011cTZ6SjJ1dlRkeFR5SlhUbWxhU2dVV1c3Rm1KZG53SW5KR3hLcHhNS3VTLWcwZGlRd3NIbEQwaWhnMFVhQkNBcjNvbkNyal9TRVpwZlBzTnRvQlNQb1lfWkQ3SUF5RWthVHBMLW1hbDJBWnc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOQlBYVVJtbXpienZvdXJsVlNMV2JOc2ZDNkp3WFRFaHNJb2Nod2g1QVlQQUhPSXR3TFVibGUzODVNc0M4dUkyLVRhN0dCT2lnNEJzRzBVa2tOSG9Ua3pvMWJTVUp4WXMyVk5lZXJRcjMxRkMydlJFUGE5X0NjYzd6Wjh5WWVBSjJBXzBPVGM3NVpKaXVycjRZY3JrdWRadzg?oc=5", "source_name": "Market source", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Altimmune, Inc. Stocks", "summary": "This article lists various ETFs that hold Altimmune, Inc. (0A4C) stocks, providing detailed information about each fund. The data includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volum", "url": "https://www.tradingview.com/symbols/LSE-0A4C/etfs/", "source_name": "TradingView", "published_at": "2026-07-04T04:40:46", "published_display": "04 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark", "summary": "Altimmune, Inc. (NasdaqGM:ALT) has been removed from the Russell Small Cap Comp Growth Benchmark. This news comes amidst other recent updates for the biopharmaceutical company, including presentations at a healthcare conference and data releases on its lead product candidate, pem", "url": "https://www.marketscreener.com/news/altimmune-inc-nasdaqgm-alt-dropped-from-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc89f725", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:56:00", "published_display": "29 Jun 2026 16:56", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark", "summary": "Altimmune, Inc. (NasdaqGM: ALT), a late clinical-stage biopharmaceutical company focused on liver disease therapies, has been removed from the Russell 2500 Growth Benchmark. The company's lead product candidate, pemvidutide, is in development for conditions such as MASH, AUD, and", "url": "https://www.marketscreener.com/news/altimmune-inc-nasdaqgm-alt-dropped-from-russell-2500-growth-benchmark-ce7f5fdfda80f626", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:30:00", "published_display": "29 Jun 2026 15:30", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index", "summary": "Altimmune, Inc. (NasdaqGM: ALT) has been added to the Russell Microcap Value Benchmark Index. This announcement was made on June 29, 2026, and is significant for the late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, includin", "url": "https://www.marketscreener.com/news/altimmune-inc-nasdaqgm-alt-added-to-russell-microcap-value-benchmark-index-ce7f5fded080f02d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:00", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark", "summary": "Altimmune, Inc. (NasdaqGM: ALT), a late clinical-stage biopharmaceutical company focusing on liver diseases, has been removed from the Russell 2000 Growth Benchmark. Despite this drop, the company continues to develop its lead product candidate, pemvidutide, for treatments like m", "url": "https://www.marketscreener.com/news/altimmune-inc-nasdaqgm-alt-dropped-from-russell-2000-growth-benchmark-ce7f5fdede8ef225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:00", "published_display": "29 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Altimmune, Inc. (NASDAQ: ALT) for alleged federal securities law violations. The lawsuit claims Altimmune made false and misleading statements regarding its Pemvidutide MASH trial and downplayed its f", "url": "https://natlawreview.com/press-releases/alt-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-altimmune-7", "source_name": "The National Law Review", "published_at": "2026-06-29T07:40:57", "published_display": "29 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Altimmune, Inc. \u2013 NASDAQ:ALT", "summary": "This article focuses on the enterprise value to revenue forward for Altimmune, Inc. (NASDAQ:ALT). It is likely a financial data point or metric provided by TradingView, indicating a key valuation measure for the biotechnology company. The content appears to be a stub or data-focu", "url": "https://www.tradingview.com/symbols/NASDAQ-ALT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:09:57", "published_display": "27 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Altimmune, Inc. \u2013 SWB:3G0", "summary": "This article provides financial information for Altimmune, Inc. (SWB:3G0), specifically focusing on its price-to-book forward ratio. The content appears to be a stub or a section of a larger financial data report, indicating that the value for this metric is available for differe", "url": "https://www.tradingview.com/symbols/SWB-3G0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:09:56", "published_display": "27 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Altimmune, Inc. \u2013 SWB:3G0", "summary": "The provided content is a financial data page for Altimmune, Inc. (SWB:3G0) on TradingView, focusing on its enterprise value to revenue forward metric. The page includes general company information, market data from the Stuttgart Stock Exchange, and various navigation elements co", "url": "https://www.tradingview.com/symbols/SWB-3G0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T12:10:36", "published_display": "27 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Altimmune, Inc. \u2013 NASDAQ:ALT", "summary": "This page provides financial information for Altimmune, Inc. (NASDAQ: ALT), focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades, and the content primarily serves as a data display from TradingView sourced from ICE Data Services", "url": "https://www.tradingview.com/symbols/NASDAQ-ALT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:39:25", "published_display": "27 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Altimmune, Inc. \u2013 NASDAQ:ALT", "summary": "This article provides the \"Price to sales forward\" financial metric for Altimmune, Inc. (NASDAQ: ALT). It appears to be a stub or a section of a larger financial data report, indicating the value and change of this specific financial ratio for the company. The content primarily f", "url": "https://www.tradingview.com/symbols/NASDAQ-ALT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:10:36", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Altimmune, Inc. \u2013 SWB:3G0", "summary": "This article provides financial information for Altimmune, Inc. (SWB:3G0) on TradingView, specifically focusing on its forward price-to-earnings ratio. It highlights that the market was closed and no trades were made at the time of publication, indicating a static financial snaps", "url": "https://www.tradingview.com/symbols/SWB-3G0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:57", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Altimmune, Inc. \u2013 BMV:ALT1", "summary": "This article focuses on the \"Price to earnings forward\" metric for Altimmune, Inc. (BMV:ALT1). The content includes financial overview elements and market data references. It appears to be a stub or a section from a larger financial analysis platform.", "url": "https://www.tradingview.com/symbols/BMV-ALT1/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:11", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker", "summary": "The drug and biotech sector is recovering from a difficult period, driven by strong M&A activity, pipeline successes, and innovation. The Zacks Medical-Drugs industry, which includes small and medium-sized drug companies, shows promising trends, with Indivior Pharmaceuticals, Aur", "url": "https://ca.finance.yahoo.com/news/zacks-industry-outlook-indivior-aurinia-085900669.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-26T03:59:00", "published_display": "26 Jun 2026 03:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Altimmune, Inc. \u2013 BMV:ALT1", "summary": "This article displays financial data, specifically the Enterprise Value to EBITDA forward, for Altimmune, Inc. (BMV:ALT1). It indicates that the market for this stock was closed with no trades recorded. The content is presented within the TradingView platform interface, emphasizi", "url": "https://www.tradingview.com/symbols/BMV-ALT1/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:41:43", "published_display": "26 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2N5Z6 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Altimmune, Inc. (A2N5Z6) stock, including analyst price targets and ratings. It details recent stock performance, future earnings expectations, and various financial metrics for the company. The current price is 2.6000 EUR, with a 1-year price", "url": "https://www.tradingview.com/symbols/LS-A2N5Z6/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:43", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?", "summary": "Altimmune, Inc. (NASDAQ:ALT) remains a \"Buy\" according to H.C. Wainwright, despite a price target reduction from $25 to $20 due to dilution from recent equity offerings. The company's strengthened funding position and progress in its MASH program are viewed positively. Recent Pha", "url": "https://www.insidermonkey.com/blog/is-altimmune-inc-alt-still-a-buy-after-price-target-reduction-to-20-1788049/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-24T14:09:55", "published_display": "24 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Altimmune at Outperform With $10 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/leerink-partners-initiates-altimmune-outperform-105115396.html", "source_name": "MT Newswires", "published_at": "2026-06-22T10:51:15+00:00", "published_display": "22 Jun 2026 10:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink initiates Altimmune stock coverage citing liver drug data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNald3U25jZ3lwcU1ieFhMamE2RlFBWlcxcWd2cVRHNDktQ3p0QTN0aGQ5WTJ4WVFkdGhtb3FaclR6UDdCd3p3dnI3LWZPQndsRk9xeWV6c2hHazg2eThxQ0U1MjlaMlRCU3Q1NHVSbC1kb0Z4dVNUQXhJMGpwZVo5RnpwZDNqTUprX21HNWVDN3RwbHIwMG5KV2NWZXc5NWtaWTg5dVQ3VmxhdC1Id01mekZ4ZWxJRlpRdUZvZWkwNHFYdlE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Altimmune Inc (ALT) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have a consensus \"Buy\" rating for ALT, with an average price target of $20.00 and a potential upside of 543.13%. The company's expected revenue ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:31", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Relocates Corporate Headquarters to Morristown, New Jersey", "summary": "Altimmune, Inc. announced its decision to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year, signing a five-year lease. This strategic move aims to leverage Morristown's dense biopharmaceutical industry presence, enhance t", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ALT/pressreleases/2524315/altimmune-relocates-corporate-headquarters-to-morristown-new-jersey/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T04:09:26", "published_display": "18 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Plans to Move Headquarters to New Jersey", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/altimmune-plans-move-headquarters-jersey-120318532.html", "source_name": "MT Newswires", "published_at": "2026-06-17T12:03:18+00:00", "published_display": "17 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune moving headquarters from Gaithersburg to New Jersey", "summary": "Altimmune is relocating its headquarters from Gaithersburg, Maryland, to New Jersey, citing cost efficiencies and better access to top-tier talent", "url": "https://www.bizjournals.com/washington/news/2026/06/17/altimmune-headquarters-maryland-new-jersey.html", "source_name": "The Business Journals", "published_at": "2026-06-17T12:11:08", "published_display": "17 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide\u2019s Broader Metabolic Data", "summary": "Altimmune (NASDAQ:ALT) is advancing its lead drug candidate, pemvidutide, for MASH, a serious liver disease. Recent 48-week data from its IMPACT Phase 2b study showed improvements in metabolic health measures, including triglycerides and cholesterol, and the company plans to star", "url": "https://www.insidermonkey.com/blog/why-altimmune-alt-could-strengthen-its-mash-case-with-pemvidutides-broader-metabolic-data-1783029/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:16:00", "published_display": "17 Jun 2026 11:16", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Relocating Headquarters from Maryland to New Jersey", "summary": "Altimmune, Inc. (NASDAQ: ALT) is moving its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year. This strategic relocation aims to enhance access to biopharmaceutical talent and improve operational efficiencies, positioning the company w", "url": "https://www.citybiz.co/article/861464/altimmune-relocating-headquarters-from-maryland-to-new-jersey/", "source_name": "citybiz", "published_at": "2026-06-17T11:11:08", "published_display": "17 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Inc (ALT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Altimmune Inc's (ALT) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and provides no data on stock splits. The piece presents basic financial information for Altimmune, i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T06:11:08", "published_display": "17 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune (ALT) plans New Jersey HQ move with 5-year lease", "summary": "Altimmune, Inc. (ALT) announced its plans to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year. The move to the new biopharmaceutical hub is expected to support talent recruitment and achieve long-term cost efficiencies. A", "url": "https://www.stocktitan.net/sec-filings/ALT/8-k-altimmune-inc-reports-material-event-58b3e7ed4ed3.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:08:53", "published_display": "16 Jun 2026 20:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Small Cap Stocks with Potential to Rise 1000 Percent", "summary": "This article highlights Altimmune, Inc. (NASDAQ:ALT) as one of five small-cap stocks with significant growth potential, possibly rising 1000 percent. Altimmune is a late-clinical stage biotechnology company developing pemvidutide for serious liver diseases like MASH, alcohol use ", "url": "https://www.insidermonkey.com/blog/5-small-cap-stocks-with-potential-to-rise-1000-percent-1782074/4", "source_name": "Insider Monkey", "published_at": "2026-06-16T14:08:53", "published_display": "16 Jun 2026 14:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPSEhFa24wcGgzVXA0MkVKMXBUaXhHcWhjZUk0VWZpaHpmdDNEZjZ6bzR1WHNSNDd5TGpHeks0cHE4Y25KTjlqTWNORXdCcVJIN0k3c3BGMjJBU2NxRjBjVkJHY3JXdy1MZHVva0dxaWVpSWpPc3NJb0tDTDFqU19TWnhaTmpiVzk4cmQzbWxYeGdsN21R?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Sets Pemvidutide\u2019s Phase 3 MASH Playbook as AUD Data Near", "summary": "Altimmune management outlined their strategy for pemvidutide, their lead metabolic and liver disease drug candidate, at the Goldman Sachs Global Healthcare Conference. The company is primarily focusing on pemvidutide's Phase 3 program for metabolic dysfunction-associated steatohe", "url": "https://www.tradingview.com/news/marketbeat:4f4427b3c094b:0-altimmune-sets-pemvidutide-s-phase-3-mash-playbook-as-aud-data-near/", "source_name": "TradingView", "published_at": "2026-06-10T23:40:08", "published_display": "10 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Several Insiders Invested In Altimmune Flagging Positive News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbzM3cC1rUy1vZTBLYVhlRlFjSk5rQUZoLVBndVFlSGFrWDZZZ3VxU3pYbUhaS0pKNkh3VXhndnFSWW5nTkFpd0I4YzFEamxxWi1wV1o2Q1hsTmlqd29OLTNIdmR3SWlvOFdGcm9JQkJEZEpDOUwwNXM3ZzFua2VGTm9GYXBhXzR6UXZobjdmbUFRUDF1d0RDdThOdmhQb1huWXBHaEhNY2o?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotech Altimmune banks $535M, plans Phase 3 liver trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNQjEwZVVxZ0tLQzJyWTZrN3UxNmxrclplSjFvQ0VfV3Q2dXB1ZTVWTndMajJNX3pBdTVEaEQtWlkzNzd5dDJlQ3Q1QndkRW5GbG4xd3JPODBmWDcycEtEajNxNUJZaGdRLU1ITjdfUzR1MlpCbGpULVc1RnI4TzRsSVJGQUwtb0gwdTNuU2tybUJaeUR0SE13ek05OFJ1ZXBQVTVFdzYySDRHV2tLNkZIdnN2SDU?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALTIMMUNE ($ALT) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQQUdZQ1hBNXAzUlFRaWpkZXNScXFKbDlraUdwT0VkR3JIeGJJWmtQUk5jb3liT0dUXzFuRnJEQmxCZ1VqTk53R2VXLW5hVWVkZHp3NUNKdzFiYktLV0ViVUQwU1l3WjJfbHc4aVdTWTFacVptTHpiUGZWT19YMEQyekxUSXIyTkx5?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "May 13: Altimmune to post Q1 results, give business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOOHlGbFdZS0pKS2JmaUZKZUx0TjJhT3VDYy1iU2NZak1XdGtTSGEyZkpSVWVhSTRySldnalRMVGVLZ0pkRlktYXNIanF4LWFuLWZLNmFMVnNmZ05HaVU4cS1DUVRFSC1vTkszM2luaE8wY2pIWkZfNFd1WXY1OVhfR1NPQWt0dnpuZ1k3Tm85c3c4ZkY4VUNrbzV6OWVwY3dVcDhCUHd1M0xmaW9yME5NR0J2V19OTk02bUhxeGtORQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPZTFtVmZIYm5GRjNrZElVRk1iMjRzVmVXNmZ0bV82aUZaT2pOeVJHa29HTHE1Qko0YWx6TUhuMzM2U0FFN3gyWTR3UGxhajJlc1BGNHVkWWNxcXBWNVgydXRNbVpCdnltR0kwLU00VnBTcDhXQkhsZDdGQzFTM2VMTXVDdVIteHplVXppSUV5ZmswU0lSOVlBS013?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "$225M Altimmune raise is slated to fund a Phase 3 MASH trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNYTFLUVYzNmpQSDR4V0EyWDJUTlZqMF9NN0dtMTBzQmxlRlRHVHhYU0MxaW9ETVoxUzNFYjFqRlFBNUZySkJSRURTMFJCQ0R3c2d6bzJtaU9MMHdRT25nWDhWLWJ3c0c1R0dyejZMSDZSTnVKaW5wa3hjV0x3Y1BlWlN6WGhYcDk1NFBJTi1VcUt1aFBaVzFCTkZVaTBwS2Y2d0RpTzEtbEI0MTBzMUQ1QmctaFpUN1pfcXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune seeks Phase 3 liver trial funds in stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQOVdvUTJhZ2FIRGtBbmRvR1pHejM2cnZvZm1rUkQyVHFMdWZJR0l0TlFZeDBHTjZ4bE5rQnBfc0FJWjRMZ21BZWhScWcwWHdBTHdUZTFyWGhMdy1PaDlzWW9HWDFmUnlpYmx6RXVfQkdHUFpPTW9GZGlXNHp5OWxWNTF4d3VJaXR1R2JpTUxFR19vNGFDY0E5Wm1RYXc3cHJnZVZWTDZUWmdQaUx3Y3lpOVU1ekk?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQUDJpZmFoSW0zdWFxbnJMUnF4UEJ4LWZEMktBNmdfV2dqTk5ROThjemd2blZLRnN0dE10eGNLdXNvQ0dMem9ydkxhSnVTQ09Ia1JCOWZKWV92d0VBQ2V6Xy1BbEtrVWpBcEd1Z0p1cGRCWGZ2YnpYWU5fdDhKVU5vZkpyMnQyVGx2MU9QUVFaOGJtaHN2UWdFZkkzb3p3LWgyS09lR1lydw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune launches stock and warrant offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNdjlqTVIxQnFhNG1pLWdnMnFJQ0R6YkVLYWs3dDZndlk5LWtZTTlRbDU1ZHpob1FCdFVGSUpQamw5WXZfYkN2R3lVbFdwdTVGNWgxYTlKYjhDajFNLWF4TGJ3ODRSMzdDdU4zdEpoS19tSXlUTnMzNGpDZUFpWFRVd0psQnV3QzR1TFZySUlvMjlVckpBaFZxV1lqUEd0blpzc1doUw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPc2c1YmF2RUV1cS1QeFNtRGs4WWpXMm9YTmxvYl96d1ZJdXU2ZW5YaUhvX21hbS11ZWE0MGhqQmZ3U2FKYWRMejNYMlVjV0JmaHRnTzFPeTM4NnlnUlBTRWFCSEJjNUNENDZUb0NPeWdKcWg5SUVKQWdYTXVjUjRtYnFZOU1FblNZbWFubmRuX0RBbmt0TGJqWHdfYXBhdHlnMEpOMnc1MVVVVDBnemM3dEg3N2Q2ZlpNRVdLZjBSbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPT2tpTk40TVdZMkVMWXMzdENHLTVmeVZKdkFxTW9uNVpPM3pLUU5oU21GZFRzbFhFOWhqbFlQOUp1REFQVHhyZXZnMmJvZjRWMGNiaXlLX1lJNHZ6RzY3WWlZNl9NUEZMcHpWVF9zbU9sRE5jNkhFRFhVMUJuc1ZsRlRZVWtmQUV5WWFsNmtnNzd5a0lvY2hnRkxMTlk5ZUhpdnRXTmpTeEF1QjE0SEYyV2xaZFo2c1RUbnNoTXY0RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxONWg0bWxwMngyM1MxbW5sWVRaNjExdjhoYmc4UkpXaWdWSDN3bGpLeFJGc2YtNjUyc2dVNzB3TTFSRXotTWptTktSWEgyTm8yYlRBMTBILV90bEtUSzJlQjVUeUtGUld5X0JIcGRBZ3RLTHl2RFo4MFE3U0RRTG5QYTl3d2Y4dTkwUTlpbQ?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune (ALT) Valuation Check After Pemvidutide\u2019s FDA Breakthrough Therapy Designation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-25T08:00:00+00:00", "published_display": "25 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNeTlmMVlkNEpUd0JNQnpjVHRYQmotM0FJNVhiTjR0OTRJU1psbzZDTmhOTE5WU3pySzlSVEh1MUUyMFhzbTRRbWpKbjBtOGU4X2JlSkxxN2NPM3AwNVotOGFxV3RENG02UC14cEtpSHItYVhuTHhXMFo1VXBrZUtYOWE1cTktbDFSMHNBVGNQVTBSWHpMQlcxcExldi1xWnB2N3p1Z21ENERKMXdBM0hlWE9HS2hmUEtaeHc?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxPaVdPbU9iWmVHanNOVjFkR0xBM3NOOElkaFo1bV9zTU5aUG41bHlNNEJzUkFVYWZVR3lUMkJGTzdOdnpCeThNdnl6SDF3NXM5bzhYVFN2TG1lQUdiSkdQSHk5UTU1YnNRdFlyb1VDVndfQzZ0Nkx4enRrRms3dVJVcElIV2swak5lQTZHSnQyY2xDeExNdWJhZjNBWlRpUnQ4WUV6d1cwNXhUVEREN3doS1hDSmFoNnloX3E3b181WHRtZ1BlV0pwMzdYNnE4TGNUQkZVUHhCS1Q4ZFB0a3NqcFFlX0h3Nm8wZ0tDYjhjTWFFSHdKbjJoOFZzSmk3SzdNa2pZeVBtQ2o?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?", "summary": "Despite Altimmune (ALT) stock experiencing a 45% drop over the last year, Wall Street analysts are projecting a significant upside, with an average 12-month price target of $18, suggesting a potential 495% increase from its current $3.02 trading price. Nine out of eleven analysts", "url": "https://stocktwits.com/news-articles/markets/equity/alt-stock-nearly-halved-in-past-year-but-wall-street-sees-almost-500-percent-upside/cZ3HgAcRImK", "source_name": "Stocktwits", "published_at": "2026-07-16T18:41:22", "published_display": "16 Jul 2026 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune gets analyst boost as MASH data grow", "summary": "Altimmune received an \"Outperform\" rating and a $10 price target from Leerink, a specialized healthcare investment bank, due to growing confidence in its drug pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH). Clinical data from the IMPACT Phase 2b trial sho", "url": "https://longevity.technology/news/altimmune-gets-analyst-boost-as-mash-data-grow/", "source_name": "Longevity.Technology", "published_at": "2026-07-09T16:05:44", "published_display": "09 Jul 2026 16:05", "sentiment": "positive", "sentiment_pct": 70, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc. Actuals & Estimates (DUS:3G0)", "summary": "This article provides actual financial data and analyst estimates for Altimmune, Inc. (DUS:3G0), including income statements, balance sheets, and cash flow information. It details financial performance, future price forecasts from analysts, historical stock prices, and upcoming e", "url": "https://www.tradingview.com/symbols/DUS-3G0/forecast-actuals-and-estimates/?category=balance_sheet", "source_name": "TradingView", "published_at": "2026-07-09T04:39:58", "published_display": "09 Jul 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune: Pemvidutide AUD Data Due Q3 Makes For Intriguing Catalyst - Upgrade (ALT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxOUVc4OWdGMmZrVjh3dG9Kdlk4ejhsM1dMX3FQMHlCYng1cHBOVDdLV3BoMzk2ZnNMVllfZS1Eb25WTEtpbV8tYkppX011cTZ6SjJ1dlRkeFR5SlhUbWxhU2dVV1c3Rm1KZG53SW5KR3hLcHhNS3VTLWcwZGlRd3NIbEQwaWhnMFVhQkNBcjNvbkNyal9TRVpwZlBzTnRvQlNQb1lfWkQ3SUF5RWthVHBMLW1hbDJBWnc?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-07T07:00:00+00:00", "published_display": "07 Jul 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Sees Altimmune (ALT) As An Attractive Play In The MASH Therapeutics Market", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxOQlBYVVJtbXpienZvdXJsVlNMV2JOc2ZDNkp3WFRFaHNJb2Nod2g1QVlQQUhPSXR3TFVibGUzODVNc0M4dUkyLVRhN0dCT2lnNEJzRzBVa2tOSG9Ua3pvMWJTVUp4WXMyVk5lZXJRcjMxRkMydlJFUGE5X0NjYzd6Wjh5WWVBSjJBXzBPVGM3NVpKaXVycjRZY3JrdWRadzg?oc=5", "source_name": "Market source", "published_at": "2026-07-05T07:00:00+00:00", "published_display": "05 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Altimmune, Inc. Stocks", "summary": "This article lists various ETFs that hold Altimmune, Inc. (0A4C) stocks, providing detailed information about each fund. The data includes market value, weight, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volum", "url": "https://www.tradingview.com/symbols/LSE-0A4C/etfs/", "source_name": "TradingView", "published_at": "2026-07-04T04:40:46", "published_display": "04 Jul 2026 04:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Small Cap Comp Growth Benchmark", "summary": "Altimmune, Inc. (NasdaqGM:ALT) has been removed from the Russell Small Cap Comp Growth Benchmark. This news comes amidst other recent updates for the biopharmaceutical company, including presentations at a healthcare conference and data releases on its lead product candidate, pem", "url": "https://www.marketscreener.com/news/altimmune-inc-nasdaqgm-alt-dropped-from-russell-small-cap-comp-growth-benchmark-ce7f5fdfdc89f725", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T16:56:00", "published_display": "29 Jun 2026 16:56", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2500 Growth Benchmark", "summary": "Altimmune, Inc. (NasdaqGM: ALT), a late clinical-stage biopharmaceutical company focused on liver disease therapies, has been removed from the Russell 2500 Growth Benchmark. The company's lead product candidate, pemvidutide, is in development for conditions such as MASH, AUD, and", "url": "https://www.marketscreener.com/news/altimmune-inc-nasdaqgm-alt-dropped-from-russell-2500-growth-benchmark-ce7f5fdfda80f626", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T15:30:00", "published_display": "29 Jun 2026 15:30", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc.(NasdaqGM: ALT) added to Russell Microcap Value Benchmark Index", "summary": "Altimmune, Inc. (NasdaqGM: ALT) has been added to the Russell Microcap Value Benchmark Index. This announcement was made on June 29, 2026, and is significant for the late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases, includin", "url": "https://www.marketscreener.com/news/altimmune-inc-nasdaqgm-alt-added-to-russell-microcap-value-benchmark-index-ce7f5fded080f02d", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T13:40:00", "published_display": "29 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune, Inc.(NasdaqGM: ALT) dropped from Russell 2000 Growth Benchmark", "summary": "Altimmune, Inc. (NasdaqGM: ALT), a late clinical-stage biopharmaceutical company focusing on liver diseases, has been removed from the Russell 2000 Growth Benchmark. Despite this drop, the company continues to develop its lead product candidate, pemvidutide, for treatments like m", "url": "https://www.marketscreener.com/news/altimmune-inc-nasdaqgm-alt-dropped-from-russell-2000-growth-benchmark-ce7f5fdede8ef225", "source_name": "www.marketscreener.com", "published_at": "2026-06-29T10:40:00", "published_display": "29 Jun 2026 10:40", "sentiment": "negative", "sentiment_pct": 29, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce", "summary": "Bronstein, Gewirtz & Grossman, LLC has announced a class action lawsuit against Altimmune, Inc. (NASDAQ: ALT) for alleged federal securities law violations. The lawsuit claims Altimmune made false and misleading statements regarding its Pemvidutide MASH trial and downplayed its f", "url": "https://natlawreview.com/press-releases/alt-investor-alert-bronstein-gewirtz-and-grossman-llc-announces-altimmune-7", "source_name": "The National Law Review", "published_at": "2026-06-29T07:40:57", "published_display": "29 Jun 2026 07:40", "sentiment": "negative", "sentiment_pct": 20, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Altimmune, Inc. \u2013 NASDAQ:ALT", "summary": "This article focuses on the enterprise value to revenue forward for Altimmune, Inc. (NASDAQ:ALT). It is likely a financial data point or metric provided by TradingView, indicating a key valuation measure for the biotechnology company. The content appears to be a stub or data-focu", "url": "https://www.tradingview.com/symbols/NASDAQ-ALT/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:09:57", "published_display": "27 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Altimmune, Inc. \u2013 SWB:3G0", "summary": "This article provides financial information for Altimmune, Inc. (SWB:3G0), specifically focusing on its price-to-book forward ratio. The content appears to be a stub or a section of a larger financial data report, indicating that the value for this metric is available for differe", "url": "https://www.tradingview.com/symbols/SWB-3G0/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T19:09:56", "published_display": "27 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Altimmune, Inc. \u2013 SWB:3G0", "summary": "The provided content is a financial data page for Altimmune, Inc. (SWB:3G0) on TradingView, focusing on its enterprise value to revenue forward metric. The page includes general company information, market data from the Stuttgart Stock Exchange, and various navigation elements co", "url": "https://www.tradingview.com/symbols/SWB-3G0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T12:10:36", "published_display": "27 Jun 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Altimmune, Inc. \u2013 NASDAQ:ALT", "summary": "This page provides financial information for Altimmune, Inc. (NASDAQ: ALT), focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades, and the content primarily serves as a data display from TradingView sourced from ICE Data Services", "url": "https://www.tradingview.com/symbols/NASDAQ-ALT/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:39:25", "published_display": "27 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Altimmune, Inc. \u2013 NASDAQ:ALT", "summary": "This article provides the \"Price to sales forward\" financial metric for Altimmune, Inc. (NASDAQ: ALT). It appears to be a stub or a section of a larger financial data report, indicating the value and change of this specific financial ratio for the company. The content primarily f", "url": "https://www.tradingview.com/symbols/NASDAQ-ALT/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T08:10:36", "published_display": "27 Jun 2026 08:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Altimmune, Inc. \u2013 SWB:3G0", "summary": "This article provides financial information for Altimmune, Inc. (SWB:3G0) on TradingView, specifically focusing on its forward price-to-earnings ratio. It highlights that the market was closed and no trades were made at the time of publication, indicating a static financial snaps", "url": "https://www.tradingview.com/symbols/SWB-3G0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T07:40:57", "published_display": "27 Jun 2026 07:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Altimmune, Inc. \u2013 BMV:ALT1", "summary": "This article focuses on the \"Price to earnings forward\" metric for Altimmune, Inc. (BMV:ALT1). The content includes financial overview elements and market data references. It appears to be a stub or a section from a larger financial analysis platform.", "url": "https://www.tradingview.com/symbols/BMV-ALT1/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T09:09:11", "published_display": "26 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Zacks Industry Outlook Indivior, Aurinia, Ironwood, Altimmune and Marker", "summary": "The drug and biotech sector is recovering from a difficult period, driven by strong M&A activity, pipeline successes, and innovation. The Zacks Medical-Drugs industry, which includes small and medium-sized drug companies, shows promising trends, with Indivior Pharmaceuticals, Aur", "url": "https://ca.finance.yahoo.com/news/zacks-industry-outlook-indivior-aurinia-085900669.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-26T03:59:00", "published_display": "26 Jun 2026 03:59", "sentiment": "positive", "sentiment_pct": 66, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Altimmune, Inc. \u2013 BMV:ALT1", "summary": "This article displays financial data, specifically the Enterprise Value to EBITDA forward, for Altimmune, Inc. (BMV:ALT1). It indicates that the market for this stock was closed with no trades recorded. The content is presented within the TradingView platform interface, emphasizi", "url": "https://www.tradingview.com/symbols/BMV-ALT1/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T02:41:43", "published_display": "26 Jun 2026 02:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A2N5Z6 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast for Altimmune, Inc. (A2N5Z6) stock, including analyst price targets and ratings. It details recent stock performance, future earnings expectations, and various financial metrics for the company. The current price is 2.6000 EUR, with a 1-year price", "url": "https://www.tradingview.com/symbols/LS-A2N5Z6/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-25T16:41:43", "published_display": "25 Jun 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Altimmune, Inc. (ALT) Still a Buy After Price Target Reduction to $20?", "summary": "Altimmune, Inc. (NASDAQ:ALT) remains a \"Buy\" according to H.C. Wainwright, despite a price target reduction from $25 to $20 due to dilution from recent equity offerings. The company's strengthened funding position and progress in its MASH program are viewed positively. Recent Pha", "url": "https://www.insidermonkey.com/blog/is-altimmune-inc-alt-still-a-buy-after-price-target-reduction-to-20-1788049/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-24T14:09:55", "published_display": "24 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 62, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink Partners Initiates Altimmune at Outperform With $10 Price Target", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/leerink-partners-initiates-altimmune-outperform-105115396.html", "source_name": "MT Newswires", "published_at": "2026-06-22T10:51:15+00:00", "published_display": "22 Jun 2026 10:51", "sentiment": "positive", "sentiment_pct": 58, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Leerink initiates Altimmune stock coverage citing liver drug data", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwwFBVV95cUxNald3U25jZ3lwcU1ieFhMamE2RlFBWlcxcWd2cVRHNDktQ3p0QTN0aGQ5WTJ4WVFkdGhtb3FaclR6UDdCd3p3dnI3LWZPQndsRk9xeWV6c2hHazg2eThxQ0U1MjlaMlRCU3Q1NHVSbC1kb0Z4dVNUQXhJMGpwZVo5RnpwZDNqTUprX21HNWVDN3RwbHIwMG5KV2NWZXc5NWtaWTg5dVQ3VmxhdC1Id01mekZ4ZWxJRlpRdUZvZWkwNHFYdlE?oc=5", "source_name": "Investing.com", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Inc (ALT) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Altimmune Inc (ALT) has an earnings forecast score of 8.00, placing it 163rd in the Biotechnology & Medical Research industry. Analysts have a consensus \"Buy\" rating for ALT, with an average price target of $20.00 and a potential upside of 543.13%. The company's expected revenue ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alt/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:31", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Relocates Corporate Headquarters to Morristown, New Jersey", "summary": "Altimmune, Inc. announced its decision to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year, signing a five-year lease. This strategic move aims to leverage Morristown's dense biopharmaceutical industry presence, enhance t", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ALT/pressreleases/2524315/altimmune-relocates-corporate-headquarters-to-morristown-new-jersey/", "source_name": "The Globe and Mail", "published_at": "2026-06-18T04:09:26", "published_display": "18 Jun 2026 04:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Plans to Move Headquarters to New Jersey", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/altimmune-plans-move-headquarters-jersey-120318532.html", "source_name": "MT Newswires", "published_at": "2026-06-17T12:03:18+00:00", "published_display": "17 Jun 2026 12:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune moving headquarters from Gaithersburg to New Jersey", "summary": "Altimmune is relocating its headquarters from Gaithersburg, Maryland, to New Jersey, citing cost efficiencies and better access to top-tier talent", "url": "https://www.bizjournals.com/washington/news/2026/06/17/altimmune-headquarters-maryland-new-jersey.html", "source_name": "The Business Journals", "published_at": "2026-06-17T12:11:08", "published_display": "17 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Altimmune (ALT) Could Strengthen Its MASH Case With Pemvidutide\u2019s Broader Metabolic Data", "summary": "Altimmune (NASDAQ:ALT) is advancing its lead drug candidate, pemvidutide, for MASH, a serious liver disease. Recent 48-week data from its IMPACT Phase 2b study showed improvements in metabolic health measures, including triglycerides and cholesterol, and the company plans to star", "url": "https://www.insidermonkey.com/blog/why-altimmune-alt-could-strengthen-its-mash-case-with-pemvidutides-broader-metabolic-data-1783029/?amp=1", "source_name": "Insider Monkey", "published_at": "2026-06-17T11:16:00", "published_display": "17 Jun 2026 11:16", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Relocating Headquarters from Maryland to New Jersey", "summary": "Altimmune, Inc. (NASDAQ: ALT) is moving its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year. This strategic relocation aims to enhance access to biopharmaceutical talent and improve operational efficiencies, positioning the company w", "url": "https://www.citybiz.co/article/861464/altimmune-relocating-headquarters-from-maryland-to-new-jersey/", "source_name": "citybiz", "published_at": "2026-06-17T11:11:08", "published_display": "17 Jun 2026 11:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Inc (ALT) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Altimmune Inc's (ALT) dividend and stock split history. It states that the company has not distributed any dividends over the past five years and provides no data on stock splits. The piece presents basic financial information for Altimmune, i", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-alt/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T06:11:08", "published_display": "17 Jun 2026 06:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune (ALT) plans New Jersey HQ move with 5-year lease", "summary": "Altimmune, Inc. (ALT) announced its plans to relocate its corporate headquarters from Gaithersburg, Maryland, to Morristown, New Jersey, later this year. The move to the new biopharmaceutical hub is expected to support talent recruitment and achieve long-term cost efficiencies. A", "url": "https://www.stocktitan.net/sec-filings/ALT/8-k-altimmune-inc-reports-material-event-58b3e7ed4ed3.html", "source_name": "Stock Titan", "published_at": "2026-06-16T20:08:53", "published_display": "16 Jun 2026 20:08", "sentiment": "positive", "sentiment_pct": 60, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Small Cap Stocks with Potential to Rise 1000 Percent", "summary": "This article highlights Altimmune, Inc. (NASDAQ:ALT) as one of five small-cap stocks with significant growth potential, possibly rising 1000 percent. Altimmune is a late-clinical stage biotechnology company developing pemvidutide for serious liver diseases like MASH, alcohol use ", "url": "https://www.insidermonkey.com/blog/5-small-cap-stocks-with-potential-to-rise-1000-percent-1782074/4", "source_name": "Insider Monkey", "published_at": "2026-06-16T14:08:53", "published_display": "16 Jun 2026 14:08", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report?", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxPSEhFa24wcGgzVXA0MkVKMXBUaXhHcWhjZUk0VWZpaHpmdDNEZjZ6bzR1WHNSNDd5TGpHeks0cHE4Y25KTjlqTWNORXdCcVJIN0k3c3BGMjJBU2NxRjBjVkJHY3JXdy1MZHVva0dxaWVpSWpPc3NJb0tDTDFqU19TWnhaTmpiVzk4cmQzbWxYeGdsN21R?oc=5", "source_name": "Market source", "published_at": "2026-06-12T07:00:00+00:00", "published_display": "12 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Sets Pemvidutide\u2019s Phase 3 MASH Playbook as AUD Data Near", "summary": "Altimmune management outlined their strategy for pemvidutide, their lead metabolic and liver disease drug candidate, at the Goldman Sachs Global Healthcare Conference. The company is primarily focusing on pemvidutide's Phase 3 program for metabolic dysfunction-associated steatohe", "url": "https://www.tradingview.com/news/marketbeat:4f4427b3c094b:0-altimmune-sets-pemvidutide-s-phase-3-mash-playbook-as-aud-data-near/", "source_name": "TradingView", "published_at": "2026-06-10T23:40:08", "published_display": "10 Jun 2026 23:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Several Insiders Invested In Altimmune Flagging Positive News", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune's Q1 Loss Narrower Than Expected, Revenues Nil", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNbzM3cC1rUy1vZTBLYVhlRlFjSk5rQUZoLVBndVFlSGFrWDZZZ3VxU3pYbUhaS0pKNkh3VXhndnFSWW5nTkFpd0I4YzFEamxxWi1wV1o2Q1hsTmlqd29OLTNIdmR3SWlvOFdGcm9JQkJEZEpDOUwwNXM3ZzFua2VGTm9GYXBhXzR6UXZobjdmbUFRUDF1d0RDdThOdmhQb1huWXBHaEhNY2o?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Altimmune banks $535M, plans Phase 3 liver trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNQjEwZVVxZ0tLQzJyWTZrN3UxNmxrclplSjFvQ0VfV3Q2dXB1ZTVWTndMajJNX3pBdTVEaEQtWlkzNzd5dDJlQ3Q1QndkRW5GbG4xd3JPODBmWDcycEtEajNxNUJZaGdRLU1ITjdfUzR1MlpCbGpULVc1RnI4TzRsSVJGQUwtb0gwdTNuU2tybUJaeUR0SE13ek05OFJ1ZXBQVTVFdzYySDRHV2tLNkZIdnN2SDU?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ALTIMMUNE ($ALT) Releases Q1 2026 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAFBVV95cUxQQUdZQ1hBNXAzUlFRaWpkZXNScXFKbDlraUdwT0VkR3JIeGJJWmtQUk5jb3liT0dUXzFuRnJEQmxCZ1VqTk53R2VXLW5hVWVkZHp3NUNKdzFiYktLV0ViVUQwU1l3WjJfbHc4aVdTWTFacVptTHpiUGZWT19YMEQyekxUSXIyTkx5?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "May 13: Altimmune to post Q1 results, give business update", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxOOHlGbFdZS0pKS2JmaUZKZUx0TjJhT3VDYy1iU2NZak1XdGtTSGEyZkpSVWVhSTRySldnalRMVGVLZ0pkRlktYXNIanF4LWFuLWZLNmFMVnNmZ05HaVU4cS1DUVRFSC1vTkszM2luaE8wY2pIWkZfNFd1WXY1OVhfR1NPQWt0dnpuZ1k3Tm85c3c4ZkY4VUNrbzV6OWVwY3dVcDhCUHd1M0xmaW9yME5NR0J2V19OTk02bUhxeGtORQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here is Why Altimmune Inc. (ALT) Appears to be an Attractive Penny Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPZTFtVmZIYm5GRjNrZElVRk1iMjRzVmVXNmZ0bV82aUZaT2pOeVJHa29HTHE1Qko0YWx6TUhuMzM2U0FFN3gyWTR3UGxhajJlc1BGNHVkWWNxcXBWNVgydXRNbVpCdnltR0kwLU00VnBTcDhXQkhsZDdGQzFTM2VMTXVDdVIteHplVXppSUV5ZmswU0lSOVlBS013?oc=5", "source_name": "Market source", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "$225M Altimmune raise is slated to fund a Phase 3 MASH trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNYTFLUVYzNmpQSDR4V0EyWDJUTlZqMF9NN0dtMTBzQmxlRlRHVHhYU0MxaW9ETVoxUzNFYjFqRlFBNUZySkJSRURTMFJCQ0R3c2d6bzJtaU9MMHdRT25nWDhWLWJ3c0c1R0dyejZMSDZSTnVKaW5wa3hjV0x3Y1BlWlN6WGhYcDk1NFBJTi1VcUt1aFBaVzFCTkZVaTBwS2Y2d0RpTzEtbEI0MTBzMUQ1QmctaFpUN1pfcXc?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune seeks Phase 3 liver trial funds in stock sale", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQOVdvUTJhZ2FIRGtBbmRvR1pHejM2cnZvZm1rUkQyVHFMdWZJR0l0TlFZeDBHTjZ4bE5rQnBfc0FJWjRMZ21BZWhScWcwWHdBTHdUZTFyWGhMdy1PaDlzWW9HWDFmUnlpYmx6RXVfQkdHUFpPTW9GZGlXNHp5OWxWNTF4d3VJaXR1R2JpTUxFR19vNGFDY0E5Wm1RYXc3cHJnZVZWTDZUWmdQaUx3Y3lpOVU1ekk?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxQUDJpZmFoSW0zdWFxbnJMUnF4UEJ4LWZEMktBNmdfV2dqTk5ROThjemd2blZLRnN0dE10eGNLdXNvQ0dMem9ydkxhSnVTQ09Ia1JCOWZKWV92d0VBQ2V6Xy1BbEtrVWpBcEd1Z0p1cGRCWGZ2YnpYWU5fdDhKVU5vZkpyMnQyVGx2MU9QUVFaOGJtaHN2UWdFZkkzb3p3LWgyS09lR1lydw?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune launches stock and warrant offering", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNdjlqTVIxQnFhNG1pLWdnMnFJQ0R6YkVLYWs3dDZndlk5LWtZTTlRbDU1ZHpob1FCdFVGSUpQamw5WXZfYkN2R3lVbFdwdTVGNWgxYTlKYjhDajFNLWF4TGJ3ODRSMzdDdU4zdEpoS19tSXlUTnMzNGpDZUFpWFRVd0psQnV3QzR1TFZySUlvMjlVckpBaFZxV1lqUEd0blpzc1doUw?oc=5", "source_name": "Investing.com", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPc2c1YmF2RUV1cS1QeFNtRGs4WWpXMm9YTmxvYl96d1ZJdXU2ZW5YaUhvX21hbS11ZWE0MGhqQmZ3U2FKYWRMejNYMlVjV0JmaHRnTzFPeTM4NnlnUlBTRWFCSEJjNUNENDZUb0NPeWdKcWg5SUVKQWdYTXVjUjRtYnFZOU1FblNZbWFubmRuX0RBbmt0TGJqWHdfYXBhdHlnMEpOMnc1MVVVVDBnemM3dEg3N2Q2ZlpNRVdLZjBSbw?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-29T08:00:00+00:00", "published_display": "29 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxPT2tpTk40TVdZMkVMWXMzdENHLTVmeVZKdkFxTW9uNVpPM3pLUU5oU21GZFRzbFhFOWhqbFlQOUp1REFQVHhyZXZnMmJvZjRWMGNiaXlLX1lJNHZ6RzY3WWlZNl9NUEZMcHpWVF9zbU9sRE5jNkhFRFhVMUJuc1ZsRlRZVWtmQUV5WWFsNmtnNzd5a0lvY2hnRkxMTlk5ZUhpdnRXTmpTeEF1QjE0SEYyV2xaZFo2c1RUbnNoTXY0RQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxONWg0bWxwMngyM1MxbW5sWVRaNjExdjhoYmc4UkpXaWdWSDN3bGpLeFJGc2YtNjUyc2dVNzB3TTFSRXotTWptTktSWEgyTm8yYlRBMTBILV90bEtUSzJlQjVUeUtGUld5X0JIcGRBZ3RLTHl2RFo4MFE3U0RRTG5QYTl3d2Y4dTkwUTlpbQ?oc=5", "source_name": "Market source", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune (ALT) Valuation Check After Pemvidutide\u2019s FDA Breakthrough Therapy Designation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-27T08:00:00+00:00", "published_display": "27 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune (ALT) Is Up 29.7% After FDA Breakthrough Tag for Pemvidutide in MASH Trial", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-01-25T08:00:00+00:00", "published_display": "25 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxNeTlmMVlkNEpUd0JNQnpjVHRYQmotM0FJNVhiTjR0OTRJU1psbzZDTmhOTE5WU3pySzlSVEh1MUUyMFhzbTRRbWpKbjBtOGU4X2JlSkxxN2NPM3AwNVotOGFxV3RENG02UC14cEtpSHItYVhuTHhXMFo1VXBrZUtYOWE1cTktbDFSMHNBVGNQVTBSWHpMQlcxcExldi1xWnB2N3p1Z21ENERKMXdBM0hlWE9HS2hmUEtaeHc?oc=5", "source_name": "24/7 Wall St.", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Altimmune Stock Attracts Strong Retail Buzz As Investors Count Down To 48-Week Data For Its Fatty Liver Treatment", "summary": "", "url": "https://news.google.com/rss/articles/CBMiiAJBVV95cUxPaVdPbU9iWmVHanNOVjFkR0xBM3NOOElkaFo1bV9zTU5aUG41bHlNNEJzUkFVYWZVR3lUMkJGTzdOdnpCeThNdnl6SDF3NXM5bzhYVFN2TG1lQUdiSkdQSHk5UTU1YnNRdFlyb1VDVndfQzZ0Nkx4enRrRms3dVJVcElIV2swak5lQTZHSnQyY2xDeExNdWJhZjNBWlRpUnQ4WUV6d1cwNXhUVEREN3doS1hDSmFoNnloX3E3b181WHRtZ1BlV0pwMzdYNnE4TGNUQkZVUHhCS1Q4ZFB0a3NqcFFlX0h3Nm8wZ0tDYjhjTWFFSHdKbjJoOFZzSmk3SzdNa2pZeVBtQ2o?oc=5", "source_name": "Stocktwits", "published_at": "2025-11-16T08:00:00+00:00", "published_display": "16 Nov 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 106, "total_relevant": 60, "sentiment_summary": {"positive": 18, "negative": 6, "neutral": 36, "score": 53, "total": 60, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 80, "events": [{"event": "general", "label": "Market update", "weight": 18.15, "count": 33}, {"event": "earnings", "label": "Earnings", "weight": 7.7, "count": 16}, {"event": "analyst", "label": "Analyst action", "weight": 4.2, "count": 7}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 18, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 2.87, "latest_week": "2026-07-17", "one_week_move": -5.9, "four_week_move": 6.3, "twelve_week_move": 0.7, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.344325, "market_dynamics_buy_signal": false, "relative_strength": -32.104188, "fair_value_gap": -48.0, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 51.8156, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-5.9% over one week, +6.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 62, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "TradingView", "count": 12}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 5}, {"label": "www.marketscreener.com", "count": 4}, {"label": "Insider Monkey", "count": 3}, {"label": "Stocktwits", "count": 2}, {"label": "MT Newswires", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 52}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 33}, {"label": "Earnings", "count": 16}, {"label": "Analyst action", "count": 7}, {"label": "Regulatory and legal", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Balance sheet", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "53/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "80/100 classification confidence."}, {"label": "Company focus", "value": "52", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-5.9% over one week, +6.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside?"}], "updated_at": "2026-07-18T13:14:22.139856+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}